

## ABSTRACT

The present invention includes a number of structural analogues of UK-1. A comparision of the anticancer activity of the UK-1 analogues with their ability to inhibit  
5 the growth of methicillin-sensitive and methicillin-resistant *Staphylococcus aureus* demonstrates that a structurally simplified analogue of UK-1 retains the natural product's selective activity against cancer cells. Structurally conservative changes to UK-1 that diminish Mg<sup>2+</sup>-binding ability may result in a dramatic decrease in cancer cell cytotoxicity. The results may establish a minimum structural pharmacophore as well as a  
10 functional role for Mg<sup>2+</sup>-binding in the selective cytotoxicity of UK-1.

15

20